Orexo Future Growth
Future criteria checks 1/6
Orexo is forecast to grow earnings and revenue by 45.6% and 7.6% per annum respectively while EPS is expected to grow by 45.5% per annum.
Key information
45.6%
Earnings growth rate
45.5%
EPS growth rate
Pharmaceuticals earnings growth | 75.2% |
Revenue growth rate | 7.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 Dec 2024 |
Recent future growth updates
Recent updates
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Dec 20Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 05Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Aug 02Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 20Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
May 29Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price
Jun 14Is Orexo (STO:ORX) A Risky Investment?
Apr 27Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price
Oct 19Would Orexo (STO:ORX) Be Better Off With Less Debt?
Sep 09Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?
May 26Is Orexo (STO:ORX) Using Too Much Debt?
Apr 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 669 | -37 | -11 | 25 | 2 |
12/31/2025 | 590 | -71 | -48 | -10 | 2 |
12/31/2024 | 585 | -154 | -89 | -44 | 2 |
9/30/2024 | 596 | -105 | -46 | -41 | N/A |
6/30/2024 | 615 | -97 | -61 | -50 | N/A |
3/31/2024 | 619 | -73 | -72 | -52 | N/A |
12/31/2023 | 639 | -128 | -114 | -95 | N/A |
9/30/2023 | 629 | -201 | -172 | -141 | N/A |
6/30/2023 | 634 | -195 | -205 | -180 | N/A |
3/31/2023 | 624 | -218 | -176 | -157 | N/A |
12/31/2022 | 624 | -178 | -180 | -157 | N/A |
9/30/2022 | 612 | -152 | -203 | -188 | N/A |
6/30/2022 | 597 | -177 | -241 | -207 | N/A |
3/31/2022 | 592 | -216 | -285 | -243 | N/A |
12/31/2021 | 565 | -223 | -282 | -229 | N/A |
9/30/2021 | 580 | -207 | -239 | -160 | N/A |
6/30/2021 | 585 | -240 | -201 | -93 | N/A |
3/31/2021 | 621 | -198 | -281 | -79 | N/A |
12/31/2020 | 664 | -84 | -173 | 17 | N/A |
9/30/2020 | 743 | 4 | -94 | 84 | N/A |
6/30/2020 | 824 | 201 | 89 | 231 | N/A |
3/31/2020 | 846 | 288 | 248 | 284 | N/A |
12/31/2019 | 845 | 219 | 255 | 287 | N/A |
9/30/2019 | 834 | 232 | 286 | 302 | N/A |
6/30/2019 | 819 | 182 | 192 | 194 | N/A |
3/31/2019 | 818 | 178 | 183 | 187 | N/A |
12/31/2018 | 783 | 138 | 238 | 242 | N/A |
9/30/2018 | 747 | 113 | 144 | 147 | N/A |
6/30/2018 | 697 | 79 | N/A | 215 | N/A |
3/31/2018 | 656 | 32 | N/A | 225 | N/A |
12/31/2017 | 644 | 23 | N/A | 147 | N/A |
9/30/2017 | 637 | 19 | N/A | 241 | N/A |
6/30/2017 | 653 | 27 | N/A | 191 | N/A |
3/31/2017 | 682 | 29 | N/A | 151 | N/A |
12/31/2016 | 706 | 29 | N/A | 156 | N/A |
9/30/2016 | 752 | -57 | N/A | 84 | N/A |
6/30/2016 | 710 | -139 | N/A | -38 | N/A |
3/31/2016 | 648 | -229 | N/A | -82 | N/A |
12/31/2015 | 646 | -210 | N/A | -109 | N/A |
9/30/2015 | 636 | -95 | N/A | -116 | N/A |
6/30/2015 | 627 | -85 | N/A | -188 | N/A |
3/31/2015 | 617 | -51 | N/A | -381 | N/A |
12/31/2014 | 570 | -57 | N/A | -487 | N/A |
9/30/2014 | 449 | -146 | N/A | -593 | N/A |
6/30/2014 | 440 | -138 | N/A | -671 | N/A |
3/31/2014 | 391 | -204 | N/A | -358 | N/A |
12/31/2013 | 429 | -155 | N/A | -263 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ORX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ORX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ORX's revenue (7.6% per year) is forecast to grow faster than the Swedish market (1.3% per year).
High Growth Revenue: ORX's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 01:26 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orexo AB (publ) is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Sten Gustafsson | ABG Sundal Collier |
Klas Palin | Carnegie Commissioned Research |
Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |